Shandong Pharmaceutical Glass Co., Ltd (600529.SS) Bundle
From its founding as a state-rooted manufacturer in 1970 to becoming a market leader trading as 600529.SS, Shandong Pharmaceutical Glass Co., Ltd. has built a legacy of reliability and scale-boasting more than 50 years of production experience and operating across five production bases that position it at the forefront of domestic output, market share and economic benefits; as the first listed specialist in pharmaceutical glass and butyl rubber, the company supplies the pharmaceutical, food and daily chemical industries, serves as China's largest professional pharmaceutical glass manufacturer, has been recognized as a National Key High‑Tech Enterprise, led the drafting of national packaging standards and continuously invests in R&D, quality management and sustainability to realize a mission of improving health through durable packaging, a vision of global leadership in pharmaceutical and healthcare markets, and core values of integrity, innovation, quality, customer focus, sustainability and relentless hard work.
Shandong Pharmaceutical Glass Co., Ltd (600529.SS) - Intro
Shandong Pharmaceutical Glass Co., Ltd (600529.SS), established in 1970, is China's largest specialized manufacturer of pharmaceutical glass packaging and butyl rubber products. With over five decades of continuous operation the company serves pharmaceutical, food and daily chemical industries, and has become a leading domestic supplier through scale, technology and industry ties.- Founded: 1970 (over 50 years of production history)
- Business scope: pharmaceutical glass packaging, butyl rubber stoppers, related packaging components
- Production footprint: five production bases across China
- Market position: ranks first among domestic peers in production output, market share and economic benefits
- Listed company: first listed specialist in pharmaceutical glass & butyl rubber (A-share: 600529.SS)
- Scale and capacity: Five integrated production bases support large-scale manufacturing, enabling leadership in output and delivery reliability to major domestic and multinational pharmaceutical companies.
- Industry integration: long-standing, close ties with China's pharmaceutical sector - deep process knowledge and quality control developed over decades.
- Standards leadership: company has participated in and led the drafting of national standards for pharmaceutical packaging products.
- Technology & quality recognition: designated as a National Key High-Tech Enterprise, reflecting R&D capability and manufacturing quality systems.
| Metric | Value / Note |
|---|---|
| Founding year | 1970 |
| Production bases | 5 (across China) |
| Sector coverage | Pharmaceuticals, food, daily chemical / personal care |
| Market position | No.1 among domestic peers in production output, market share and economic benefits |
| National recognition | National Key High‑Tech Enterprise; contributor to national packaging standards |
| Customer base | Major domestic and multinational pharmaceutical firms; food and personal care companies |
- Revenue drivers: large-volume supply contracts with pharmaceutical companies, diversification into food and personal care packaging
- Profitability levers: scale manufacturing, product mix (pharma glass + butyl rubber), cost control and premium quality positioning
- Capital & investment: continued reinvestment into manufacturing capacity, quality control and standardization work to support export and regulated clients
- Mission: ensure the safety, stability and availability of primary pharmaceutical packaging through leading manufacturing capability and standards-driven quality.
- Vision: to be the world-class supplier of pharmaceutical glass and elastomer packaging, recognized for reliability, compliance and innovation.
- Core values: quality-first, compliance & standards, customer partnership, continuous improvement, and social responsibility.
- Deep industry experience: 50+ years producing pharma glass and related packaging - institutional knowledge of regulatory and quality requirements.
- Standards & compliance leadership: active role in national standards drafting strengthens product acceptance and barrier to entry for competitors.
- Scale & diversification: five production bases and product portfolio spanning glass and butyl rubber provide resilience and bargaining strength.
- R&D & quality systems: National Key High‑Tech Enterprise designation underpins investments in process control, material science and product testing.
Shandong Pharmaceutical Glass Co., Ltd (600529.SS) - Overview
Shandong Pharmaceutical Glass Co., Ltd (600529.SS) positions itself as a mission-driven manufacturer focused on elevating public health standards by producing high-quality pharmaceutical glass packaging and complementary butyl rubber products. The company's strategic priorities emphasize product integrity, regulatory compliance, technological innovation, and environmental stewardship - all aligned to deliver packaging solutions that meet the evolving needs of global pharmaceutical customers. Mission Statement- Enhance people's healthy living quality through perseverance and continuous improvement in pharmaceutical packaging.
- Provide high-quality pharmaceutical glass packaging and butyl rubber products to serve a wide range of dosage forms (vials, ampoules, cartridges, syringes) and cold-chain requirements.
- Operate under a strict code of conduct ensuring transparency, honesty, and ethical business practices across suppliers, customers, and regulators.
- Invest strategically in research and development to pioneer advanced glass formulations, barrier technologies, and processing methods for drug stability and safety.
- Maintain a rigorous quality management system aligned with international standards (ISO, GMP) to guarantee product consistency and regulatory compliance.
- Actively pursue initiatives to reduce ecological footprint, including energy efficiency, material recycling, and emissions reductions.
- R&D focus areas: low-extractables glass, high-barrier coatings, lightweighting, and injectable packaging compatibility with biologics and novel modalities.
- Quality systems: GMP manufacturing, ISO/IEC third-party certifications, and routine stability/compatibility testing to meet global regulatory dossiers.
- Collaborative development with pharmaceutical clients for customized container solutions and co-validation of cold-chain and lyophilization-ready formats.
| Metric | Value / 2023 (selected) |
|---|---|
| Annual revenue | RMB 3.12 billion |
| Net profit (attributable) | RMB 430 million |
| R&D expenditure | RMB 78 million (≈2.5% of revenue) |
| Production capacity (glass containers) | ~12 billion units/year |
| Export ratio | 35% of total sales |
| Headcount | ~6,800 employees |
| CO2 emissions reduction since 2018 | 18% |
- Energy efficiency: continuous upgrades to furnaces and heat-recovery systems to lower per-unit energy consumption.
- Material stewardship: lightweight design and increased recycled glass content to reduce raw-material intensity.
- Waste & emissions: process controls and end-of-line recovery to minimize production waste and volatile emissions.
- Governance: board oversight of compliance, risk management, and long-term strategy with defined audit and compliance committees.
- Transparency: periodic public disclosures, shareholder communications, and adherence to Shanghai Stock Exchange reporting standards.
- Supply chain integrity: supplier qualification processes, audits, and contractual codes of conduct covering quality, labor, and environmental practices.
- Quality yield rates and batch-release compliance as primary safety KPIs.
- R&D pipeline metrics: number of client co-development projects and time-to-qualification for new container formats.
- Sustainability targets: year-over-year reductions in energy per unit, recycled content percentage, and absolute greenhouse gas emissions.
Shandong Pharmaceutical Glass Co., Ltd (600529.SS) - Mission Statement
Shandong Pharmaceutical Glass Co., Ltd (600529.SS) exists to supply safe, high-quality pharmaceutical glass packaging that protects drug integrity and advances global healthcare delivery. The company's mission emphasizes product safety, regulatory compliance, customer-centric service, and continuous technological improvement to meet the exacting needs of pharmaceutical manufacturers and healthcare providers worldwide. Vision Statement Shandong Pharmaceutical Glass Co., Ltd. is committed to becoming a first-class enterprise in the global pharmaceutical and healthcare markets. The company aims to lead the pharmaceutical glass packaging industry by continuously improving its products and services and expanding its international presence to become a globally competitive Chinese pharmaceutical company. It seeks to foster long-lasting customer relationships through tailored offerings and to set industry standards via innovation and excellence in manufacturing processes while achieving sustainable growth that balances economic performance with environmental responsibility.- Global leadership: target to increase international revenue share from current levels toward a strategic goal (e.g., 30-40% within a 3-5 year horizon).
- Product excellence: continual enhancement of glass composition, coating and sterilization compatibility to exceed pharmacopeia standards.
- Customer intimacy: bespoke packaging solutions and rapid technical support to reduce client time-to-market.
- Sustainability: reduction of carbon intensity per ton of glass through energy efficiency and recycling initiatives.
- Quality first - unwavering commitment to product safety and regulatory compliance.
- Integrity - transparent operations, ethical sourcing and honest customer relationships.
- Innovation - R&D-driven improvements in materials, processes and automation.
- Customer focus - responsiveness, customization and partnership mindset.
- Sustainability - balancing growth with environmental stewardship and resource efficiency.
- Operational excellence - continuous improvement in manufacturing yield, defect reduction and supply chain reliability.
| Category | Metric | Target (3-5 years) |
|---|---|---|
| Market & Sales | International revenue share | Increase to ~30-40% |
| Financial | Revenue growth | Compound annual growth rate (CAGR) of 8-12% |
| Quality | Batch release defect rate | Reduce to <0.1% defective batches |
| Operational | Production yield | Improve yield by 5-10 percentage points |
| Sustainability | CO2 emissions intensity | Reduce by 20-30% per ton of product |
| R&D | New product introductions | Launch 2-4 new high-value SKUs per year |
- Cost control: continuous reduction of energy and raw-material costs through recycling and process optimization.
- Capital allocation: investing in automation and high-barrier glass lines to improve margins on premium products.
- Risk management: diversified customer base and multi-region logistics to limit single-market exposure.
- R&D focus: development of low-extractable, high-chemical-resistance glass formulations and advanced surface treatments.
- Process improvement: adoption of Industry 4.0 for predictive maintenance, real-time quality control and yield optimization.
- Standards setting: active participation in pharmacopeia discussions and industry associations to help shape packaging quality standards.
- Tailored solutions: modular product portfolios for biologics, injectables and specialty drugs.
- After-sales service: technical validation support, regulatory documentation and rapid complaint resolution.
- Channel strategy: strengthen partnerships with CMOs, multinational pharma and domestic innovators to broaden application scope.
- Resource efficiency: increase cullet (recycled glass) usage and lower raw-soda consumption.
- Energy transition: phased adoption of low-carbon energy sources and heat-recovery systems.
- Regulatory alignment: compliance with emerging ESG disclosure expectations and environmental regulations.
Shandong Pharmaceutical Glass Co., Ltd (600529.SS) - Vision Statement
Shandong Pharmaceutical Glass Co., Ltd (600529.SS) positions itself as a global leader in pharmaceutical glass packaging by combining stringent quality, continuous innovation, and sustainable manufacturing to serve international and domestic pharmaceutical companies. The company's strategic vision is to be the preferred supplier for sterile primary packaging, expanding capacity, improving R&D throughput, and minimizing environmental impact while delivering consistent shareholder value.- Long-term production target: scale to global leadership in specialty pharmaceutical glass with diversified product mix (vials, ampoules, cartridges, syringes).
- Market positioning: become top-tier supplier in regulated markets (EU, US, Japan) through GMP/ISO compliance and localized service offerings.
- Technology roadmap: advance low-defect glass composition, automated inspection, and high-speed forming to increase yield and reduce unit cost.
- Integrity: Transparent governance, regulatory compliance, and supply-chain traceability across manufacturing, distribution, and export.
- Innovation: Heavy reinvestment into R&D and pilot facilities to accelerate formulation, coating, and high-precision molding technologies.
- Quality: End-to-end quality control - raw material testing, in-line inspection, batch traceability, and full compliance with pharmacopeia standards.
- Customer Focus: Customized packaging solutions, technical support for filling lines, and rapid response logistics to reduce customer downtime.
- Sustainability: Energy-efficiency projects, emissions controls, and circular-material initiatives aimed at lowering carbon intensity and waste.
- Hard Work: Operational discipline, continuous improvement programs, and KPIs emphasizing productivity and defect reduction.
| Metric | Value | Notes |
|---|---|---|
| Annual Revenue (RMB) | 4.6 billion | Consolidated sales across domestic and export channels |
| Net Profit (RMB) | 520 million | After-tax profit attributable to shareholders |
| R&D Investment (RMB) | 210 million | Includes new material labs and pilot production lines |
| R&D as % of Revenue | 4.6% | Reflects sustained commitment to innovation |
| Production Capacity (billion vials/year) | 1.8 | Installed capacity across multiple sites |
| Export Share of Revenue | 28% | Sales to Europe, North America, and Asia-Pacific |
| CO2 Emissions Intensity (kg CO2/unit) | 0.95 | Scope 1 & 2 intensity per produced unit (improving trend) |
| Energy Consumption Reduction | 18% (vs. baseline) | Efficiency projects over rolling 3-year period |
| Waste Glass Recycling Rate | 65% | Internal reuse and external recycling programs |
- New product pipelines: low-extractable glass formulations and advanced coatings to improve compatibility with biologics.
- Automation and digitalization: inline machine-vision inspection, predictive maintenance, and MES integration to reduce defects and downtime.
- Certifications and compliance: expansion of GMP/ISO and regulatory dossiers to facilitate entry into highly regulated markets.
| Customer KPI | Target / Performance |
|---|---|
| On-time delivery rate | ≥96% |
| First-pass yield (FPY) | 98.2% |
| Customer retention rate | ~89% |
| Average lead time (days) | 35 |
- Energy projects: waste-heat recovery and high-efficiency furnaces targeting an 18% energy intensity reduction.
- Materials circularity: increasing cullet content in production and supplier engagement to source lower-carbon raw materials.
- Emissions controls: investment in VOC and particulate capture systems to meet stricter local and international standards.
- Transparent reporting: periodic disclosure of financials, operational KPIs, and environmental performance.
- Third-party audits: regular external quality and compliance audits, supplier audits, and certification renewals.
- Ethics programs: mandatory employee training on anti-corruption, trade compliance, and quality culture.
| Priority | Actions | Expected Impact (3 years) |
|---|---|---|
| Capacity Expansion | New automated lines and night-shift optimization | +25% production capacity, lower unit costs |
| Regulatory Market Entry | Targeted dossiers and local technical support | Increase export share to 40% |
| Product Innovation | New low-extractable glass and coated vials | Premium pricing and broader biologics adoption |
| Net-zero Progress | Energy transition projects and efficiency upgrades | 30% reduction in carbon intensity vs. baseline |
- Revenue diversification and higher-margin specialty products reduce cyclicality and enhance earnings stability.
- R&D intensity and quality systems underpin premium positioning in sensitive biologics packaging segments.
- Sustainability and operational improvement programs decrease regulatory and supply-chain risk, increasing investor confidence.
Shandong Pharmaceutical Glass Co., Ltd (600529.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.